RTOG Foundation Study 3504

Status Date:  September 27, 2018  | Status:  Terminated

Safety Evaluations of Nivolumab (Anti-PD-1) Added to Chemoradiotherapy in Patients with Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma

Principal Investigators

Maura Gillison, MD, PhD
Robert Ferris, MD, PhD

Primary Objective

To evaluate the safety of the addition of nivolumab (anti-PD-1 targeted immumotherapy) to cisplatin-based CRT, cextuximab-based CRT or RT alone in patients with intermediate or high-risk head and neck squamous cell carcinoma (HNSCC).

Patient Population

Histologically or cytologically confirmed intermediate- or high-risk HNSCC.

Participating Sites

Institution Name City State/Country
Emory University Atlanta GA
Inova Fairfax Hospital Falls Church VA
MD Anderson Cancer Center Houston TX
Providence Portland Medical Center Portland OR
Ohio State University Columbus OH
Stanford University Palo Alto CA
University Hospitals Cleveland Medical Center Cleveland OH
University of Florida Health Cancer Center Orlando FL
University of Louisville Louisville KY
University of Wisconsin Hospital and Clinics Madison WI
UPMC - Shadyside Hospital Pittsburgh PA

Participate in RTOG Research

To participate as an RTOG study investigator, your organization must be part of the RTOG Foundation network. Patients who wish to participate in a study must be under the care of an RTOG participating investigator. For additional information, email info@rtog.org or call 1-215-574-3173.

See our clinical trials